Pfizer Buys Stake in Dutch Biotech; Potential $600M Option to Purchase

Source: Nasdaq

May 11, 2015

Pfizer Inc. has purchased a minority stake in Dutch biopharmaceutical company AM-Pharma for an upfront payment of $87.5 million, with an exclusive option to buy the whole company.

If Pfizer chooses to purchase the biotech, which is working on treatments for conditions including acute kidney injury, Pfizer would pay up to $512.5 million more in the deal.

The option to buy becomes exercisable after AM-Pharma's completion of a Phase II trial of a treatment for acute kidney injury related to sepsis. Results of the trial are anticapted in the second half of 2016.

Read the Nasdaq article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments